dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Vieito Villar, Maria |
dc.contributor.author | De Vos, Filip |
dc.contributor.author | Marjolein Geurts |
dc.contributor.author | Lorenzi, Elena |
dc.contributor.author | Moreno, Victor |
dc.contributor.author | Simonelli, Matteo |
dc.date.accessioned | 2022-12-02T09:03:36Z |
dc.date.available | 2022-12-02T09:03:36Z |
dc.date.issued | 2022-01 |
dc.identifier.citation | Vieito M, Simonelli M, de Vos F, Moreno V, Geurts M, Lorenzi E, et al. Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2022 Jan-Dec;4(1):vdac146. |
dc.identifier.issn | 2632-2498 |
dc.identifier.uri | https://hdl.handle.net/11351/8583 |
dc.description | Inhibidors de BET; Glioblastoma; Farmacocinètica |
dc.description.sponsorship | This study was sponsored by Celgene, a Bristol Myers Squibb company. |
dc.language.iso | eng |
dc.publisher | Oxford University Press |
dc.relation.ispartofseries | Neuro-Oncology Advances;4(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Glioblastoma multiforme - Tractament |
dc.subject | Glioblastoma multiforme - Radioteràpia |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Glioblastoma |
dc.subject.mesh | /therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Radiotherapy |
dc.title | Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1093/noajnl/vdac146 |
dc.subject.decs | glioblastoma |
dc.subject.decs | /terapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | radioterapia |
dc.relation.publishversion | https://doi.org/10.1093/noajnl/vdac146 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Vieito M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Simonelli M] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Research Hospital, Milan, Italy. [de Vos F] Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [Moreno V] START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Geurts M] Erasmus MC Cancer Institute, Rotterdam, the Netherlands. [Lorenzi E] IRCCS Humanitas Research Hospital, Milan, Italy |
dc.identifier.pmid | 36382109 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |